Castleark Management’s Novavax NVAX Stock Holding History

Castleark Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,100	Closed	-$1.47M	–	350
2021 Q1	$1.47M	Buy	+8,100	New	+$1.61M	0.05%	197

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Castleark Management's NVAX Position: Q2 2021 in Review

Castleark Management sold out of Novavax (NVAX) in Q2 2021, closing a stake of 8,100 shares — an estimated $1.47M sold.

Castleark Management first reported a position in NVAX in Q1 2021 and held it in 1 quarter. The position peaked at $1.47M in Q1 2021. 407 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

Castleark Management reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
Castleark Management sold 8,100 Novavax shares in Q2 2021, an estimated $1.47M.
Castleark Management first reported a position in Novavax in Q1 2021 and held it in 1 quarter.
Castleark Management's Novavax position peaked at $1.47M in Q1 2021.
407 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Castleark Management's 13F filing for Q2 2021, filed 17 Aug 2021.